Deriving individual threshold doses from clinical food challenge data for population risk assessment of food allergens.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
11 2019
Historique:
received: 11 02 2019
revised: 24 06 2019
accepted: 22 07 2019
pubmed: 25 8 2019
medline: 17 6 2020
entrez: 25 8 2019
Statut: ppublish

Résumé

Food allergies are a significant public health issue, and the only effective management option currently available is strict avoidance of all foods containing the allergen. In view of the practical impossibility of limiting risks to zero, quantitative allergen risk assessment and management strategies are needed. We sought to develop appropriate methods for informing population-based risk assessments and risk management programs to benefit all stakeholders but particularly patients with food allergy. Individual thresholds for food allergens (maximum tolerable doses and minimum eliciting doses) can ideally be established through double-blind, placebo-controlled food challenges. If double-blind, placebo-controlled food challenge data are not available, data from widely used open food challenges using predefined objective criteria can also provide useful data regarding minimum eliciting doses. For more than 20 years, the Netherlands Organisation for Applied Scientific Research and the Food Allergy Research and Resource Program at the University of Nebraska-Lincoln have been collecting individual maximum tolerable doses and minimum eliciting doses that produce objective symptoms from published and unpublished clinical data to better refine knowledge regarding the sensitivity of the population to food allergens. In this article we provide in-depth insights into the methodology applied by the Netherlands Organisation for Applied Scientific Research and Food Allergy Research and Resource Program to derive individual maximum tolerable doses and minimum eliciting doses for objective symptoms from clinical food challenge data. More than 90 examples for determining individual allergic thresholds are presented. With the methodology presented in this article, we aim to stimulate harmonization and transparency in quantitative food allergen risk assessment and risk management programs, encouraging their wider adoption.

Sections du résumé

BACKGROUND
Food allergies are a significant public health issue, and the only effective management option currently available is strict avoidance of all foods containing the allergen. In view of the practical impossibility of limiting risks to zero, quantitative allergen risk assessment and management strategies are needed.
OBJECTIVE
We sought to develop appropriate methods for informing population-based risk assessments and risk management programs to benefit all stakeholders but particularly patients with food allergy.
METHODS
Individual thresholds for food allergens (maximum tolerable doses and minimum eliciting doses) can ideally be established through double-blind, placebo-controlled food challenges. If double-blind, placebo-controlled food challenge data are not available, data from widely used open food challenges using predefined objective criteria can also provide useful data regarding minimum eliciting doses. For more than 20 years, the Netherlands Organisation for Applied Scientific Research and the Food Allergy Research and Resource Program at the University of Nebraska-Lincoln have been collecting individual maximum tolerable doses and minimum eliciting doses that produce objective symptoms from published and unpublished clinical data to better refine knowledge regarding the sensitivity of the population to food allergens.
RESULTS
In this article we provide in-depth insights into the methodology applied by the Netherlands Organisation for Applied Scientific Research and Food Allergy Research and Resource Program to derive individual maximum tolerable doses and minimum eliciting doses for objective symptoms from clinical food challenge data. More than 90 examples for determining individual allergic thresholds are presented.
CONCLUSION
With the methodology presented in this article, we aim to stimulate harmonization and transparency in quantitative food allergen risk assessment and risk management programs, encouraging their wider adoption.

Identifiants

pubmed: 31445097
pii: S0091-6749(19)31093-0
doi: 10.1016/j.jaci.2019.07.046
pii:
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1290-1309

Subventions

Organisme : Medical Research Council
ID : MR/K010468/1
Pays : United Kingdom

Informations de copyright

Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Joost Westerhout (J)

Netherlands Organisation for Applied Scientific Research (TNO), Zeist, The Netherlands.

Joseph L Baumert (JL)

Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Neb.

W Marty Blom (WM)

Netherlands Organisation for Applied Scientific Research (TNO), Zeist, The Netherlands. Electronic address: marty.blom@tno.nl.

Katrina J Allen (KJ)

Murdoch Children's Research Institute and University of Melbourne School of Population and Global Health, Melbourne, Australia.

Barbara Ballmer-Weber (B)

Allergy Unit, Department of Dermatology, University Hospital, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland; Clinic for Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland.

René W R Crevel (RWR)

René Crevel Consulting, Bedford, United Kingdom.

Anthony E J Dubois (AEJ)

University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergy, GRIAC Research Institute, Groningen, The Netherlands.

Montserrat Fernández-Rivas (M)

Allergy Department, Hospital Clinico San Carlos, Universidad Complutense Madrid, Madrid, Spain.

Matthew J Greenhawt (MJ)

Children's Hospital Colorado, School of Medicine, University of Colorado, Boulder, Colo.

Jonathan O'B Hourihane (JO)

INFANT Centre and Paediatrics and Child Health, University College Cork, Cork, Ireland.

Jennifer J Koplin (JJ)

Murdoch Children's Research Institute and University of Melbourne School of Population and Global Health, Melbourne, Australia.

Astrid G Kruizinga (AG)

Netherlands Organisation for Applied Scientific Research (TNO), Zeist, The Netherlands.

Thuy-My Le (TM)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

Hugh A Sampson (HA)

Icahn School of Medicine at Mount Sinai, New York, NY.

Wayne G Shreffler (WG)

Food Allergy Centre and Centre for Immunology and Inflammatory Disease, and Massachusetts General Hospital/Harvard Medical School, Boston, Mass.

Paul J Turner (PJ)

Section of Paediatrics, Imperial College London, London, United Kingdom; Discipline of Child and Adolescent Health, University of Sydney, Sydney, Australia.

Steve L Taylor (SL)

Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Neb.

Geert F Houben (GF)

Netherlands Organisation for Applied Scientific Research (TNO), Zeist, The Netherlands.

Benjamin C Remington (BC)

Netherlands Organisation for Applied Scientific Research (TNO), Zeist, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH